Bioline Rx AI Stock Analysis
Want to see IL:BLRX full AI Analyst Report?
Bioline Rx (BLRX) AI Stock Analysis
Bioline Rx
(TASE:BLRX)
Overall score is held back primarily by very weak financial performance (collapsed TTM revenue, deep losses, and ongoing cash burn). Technicals are also unfavorable with the stock below major moving averages and negative MACD, though oversold signals provide a modest offset. The latest earnings call was comparatively constructive on clinical execution and runway into 1H 2027, which partially supports the score despite the early-stage and funding/dilution risks.
Bioline Rx (BLRX) vs. iShares MSCI Israel ETF (EIS)
- Market Cap
- ILS 29.87M
- Dividend Yield
- ―
- Average Volume (3M)
- 3.61M
- Price to Earnings (P/E)
- -1.0
- Beta (1Y)
- 0.46
- Revenue Growth
- -93.07%
- EPS Growth
- 62.25%
- Country
- Israel
- Employees
- 22
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Bioline Rx Business Overview & Revenue Model
Company Description
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatm...
How the Company Makes Money
BiolineRx generates revenue primarily through (1) collaboration/licensing arrangements and (2) to a lesser extent, other operating income typical of development-stage biotech companies. Under collaboration or licensing deals, the company may receive...
Bioline Rx Earnings Call Summary
The call was predominantly positive, driven by strong GLIX1 clinical recruitment and tolerability, encouraging preclinical efficacy and combination data, progress in the pancreatic cancer trial, APHEXDA royalty generation, and funding expected to support operations into the first half of 2027. These positives were tempered by the higher quarterly net loss and R&D spending, flat revenue, the early stage of GLIX1 clinical development, uncertainty surrounding the pancreatic cancer treatment landscape, and the commercial work still required to expand APHEXDA adoption.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
BioLineRx expects the third of 5 planned GLIX1 Phase I cohorts to commence dosing in September, with the Phase I part expected to recruit up to 30 patients and Phase I data anticipated in the first half of 2027; the Phase IIa expansion is planned to include additional cohorts, including GBM, newly diagnosed and/or recurrent, as well as additional cancers with or without standard of care, for example, PARP inhibitors. The CheMo4METPANC trial’s prespecified interim/futility analysis is planned for when 40% of progression-free survival events are observed, expected later this year. Cash and equivalents of $13.1 million are sufficient to fund the operating plan as currently contemplated into the first half of 2027, and the $3.75 million offering is expected to close later today.
Bioline Rx Financial Statement Overview
Summary
Weak fundamentals: TTM revenue is very small and down ~99% year over year, profitability remains deeply negative (TTM net margin about -572%), and cash flow is still meaningfully negative (TTM operating cash flow/free cash flow around -11M). Balance sheet leverage is moderate (debt-to-equity ~0.58) but declining equity/assets and negative ROE (~-47%) limit financial flexibility.
Income Statement
24NegativeBalance Sheet
45NeutralCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.40M | 1.28M | 28.94M | 4.80M | 0 | 0 |
| Gross Profit | 976.95K | 462.21K | 19.68M | 1.11M | 0 | 0 |
| EBITDA | -11.31M | -10.61M | 3.92M | -57.09M | -28.50M | -24.07M |
| Net Income | -8.04M | -1.27M | -9.22M | -60.61M | -20.75M | -28.14M |
Balance Sheet | ||||||
| Total Assets | 33.26M | 40.91M | 38.91M | 63.92M | 76.38M | 81.39M |
| Cash, Cash Equivalents and Short-Term Investments | 12.99M | 20.88M | 19.56M | 42.99M | 51.08M | 57.13M |
| Total Debt | 7.94M | 10.15M | 15.04M | 11.59M | 12.32M | 4.65M |
| Total Liabilities | 16.75M | 17.56M | 25.45M | 50.70M | 25.54M | 13.30M |
| Stockholders Equity | 13.68M | 18.20M | 13.46M | 13.22M | 50.84M | 68.09M |
Cash Flow | ||||||
| Free Cash Flow | -10.97M | -8.77M | -43.93M | -22.91M | -26.56M | -23.67M |
| Operating Cash Flow | -10.94M | -8.74M | -43.87M | -22.61M | -26.24M | -23.57M |
| Investing Cash Flow | 12.53M | -9.25M | 29.37M | 1.44M | 4.01M | -38.22M |
| Financing Cash Flow | -4.78M | 9.62M | 20.66M | 15.06M | 20.44M | 57.75M |
Bioline Rx Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:BLRX, the sentiment is Negative. The current price of 1.00 is below the 20-day moving average (MA) of 1.05, below the 50-day MA of 1.20, and below the 200-day MA of 1.41, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 35.69 is Neutral, neither overbought nor oversold. The STOCH value of 90.91 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:BLRX.
Bioline Rx Risk Analysis
Bioline Rx disclosed 43 risk factors in its most recent earnings report. Bioline Rx reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksBioline Rx Peers Comparison
Overall Rating
IL:BLRX48Neutral
IL:CANF38Underperform
IL:BOLT27Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 48Neutral | ILS 29.87M | -1.00 | ― | ― | -93.07% | 62.25% | |
| 38Underperform | ILS 16.23M | -0.23 | ― | ― | ― | ― | |
| 27Underperform | ILS 26.66M | -2.19 | ― | ― | -100.00% | -29.02% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IL:BLRX | BioLineRX Ltd. | 1.00 | -0.80 | -44.44% | |
| IL:XTLB | XTL Biopharmaceuticals Ltd. | 1.40 | -1.90 | -57.58% | |
| IL:CANF | Can-Fite BioPharma Ltd. | 258.90 | 257.90 | 25790.00% | |
| IL:BOLT | BioLight Life Sciences Ltd. | 293.60 | -100.80 | -25.56% | |
| IL:MTLF | Matricelf Ltd. | 246.80 | -161.20 | -39.51% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 27, 2026
